Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial

Michael Haude(Lukaskrankenhaus), Hüseyin İnce(Klinikum im Friedrichshain), Alexandre Abizaid(Instituto Dante Pazzanese de Cardiologia), Ralph Töelg(Segeberger Kliniken), Pedro A. Lemos, Clemens von Birgelen(Medisch Spectrum Twente), Evald Høj Christiansen(Aarhus University Hospital), William Wijns(Onze Lieve Vrouwziekenhuis Hospital), Franz–Josef Neumann(Universitäts-Herzzentrum Freiburg-Bad Krozingen), Christoph Kaiser(University Hospital of Basel), Éric Eeckhout(University of Lausanne), Soo Teik Lim(National Heart Centre Singapore), Javier Escaned(Hospital Clínico San Carlos), Héctor M. García‐García(Cardialysis (Netherlands)), Ron Waksman(MedStar Washington Hospital Center)
The Lancet
October 21, 2015
Cited by 352

Abstract


Related Papers

No related papers found

Powered by citation graph analysis